Conference Proceedings

Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national cohort

S Sharmin, C Malpas, I Roos, I Diouf, R Alroughani, S Ozakbas, G Izquierdo, S Eichau, D Horakova, EK Havrdova, F Patti, M Terzi, C Boz, B Yamout, SJ Khoury, M Onofrj, A Lugaresi, A Altintas, A Prat, M Girard Show all

MULTIPLE SCLEROSIS JOURNAL | SAGE PUBLICATIONS LTD | Published : 2021

Related Projects (3)

Project icon

PRECISION TREATMENT FOR MULTIPLE SCLEROSIS: MAXIMISING THE EFFECT OF IMMUNOMODULATORY THERAPY

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

Project icon

PRECISION THERAPY FOR NEUROLOGICAL DISEASES

Multiple sclerosis is the most common cause of neurological disability among young adults. The patients’ individual response to therapy is h..

Project icon

Personalised therapy to prevent disability in aggressive multiple sclerosis

Grants

Awarded by NHMRC

Awarded by National Health and Medical Research Council of Australia

Funding Acknowledgements

This study was funded by the NHMRC [grant 1129189 and fellowship 1140766]. The MSBase Foundation is a not-for-profit organization that receives support from Merck, Biogen, Novartis, Roche, Bayer Schering, Sanofi Genzyme, and Teva Pharmaceutical Industries. The study was conducted separately and apart from the guidance of the sponsors.

Keywords

Disease-Modifying Therapies
Bayesian
Life Sciences & Biomedicine
Science & Technology
Neurosciences & Neurology
Paediatric Multiple Sclerosis
Clinical Neurology
Neurosciences